Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Day

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Biochemistry|February 23, 1999
Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptorW J LaRochelle, K Sakaguchi, N Atabey, et al.
Journal of the Royal Society, Interface|June 15, 2012
Rapid magnetic cell delivery for large tubular bioengineered constructsJ Gonzalez-Molina, J Riegler, P Southern, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 14, 2000
Unusual 1H NMR chemical shifts support (His) C(epsilon) 1...O==C H-bond: proposal for reaction-driven ring flip mechanism in serine protease catalysisE L Ash, J L Sudmeier, R M Day, et al.
Journal of the American Academy of Dermatology|January 1, 1988
Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporisL E Millikan, W K Galen, G B Gewirtzman, et al.
The Journal of Biological Chemistry|July 4, 2001
Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signalingJ S Rubin, R M Day, D Breckenridge, et al.
The British Journal of Dermatology|September 12, 2015
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)C Paul, J Cather, M Gooderham, et al.
Archives of Dermatology|June 2, 1998
Consensus workshop on the toxic effects of long-term PUVA therapyW L Morison, R D Baughman, R M Day, et al.
Journal of the American Academy of Dermatology|July 25, 2000
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?G G Krueger, S R Feldman, C Camisa, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Biochemistry|February 23, 1999
Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptorW J LaRochelle, K Sakaguchi, N Atabey, et al.
Journal of the Royal Society, Interface|June 15, 2012
Rapid magnetic cell delivery for large tubular bioengineered constructsJ Gonzalez-Molina, J Riegler, P Southern, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 14, 2000
Unusual 1H NMR chemical shifts support (His) C(epsilon) 1...O==C H-bond: proposal for reaction-driven ring flip mechanism in serine protease catalysisE L Ash, J L Sudmeier, R M Day, et al.
Journal of the American Academy of Dermatology|January 1, 1988
Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporisL E Millikan, W K Galen, G B Gewirtzman, et al.
The Journal of Biological Chemistry|July 4, 2001
Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signalingJ S Rubin, R M Day, D Breckenridge, et al.
The British Journal of Dermatology|September 12, 2015
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)C Paul, J Cather, M Gooderham, et al.
Archives of Dermatology|June 2, 1998
Consensus workshop on the toxic effects of long-term PUVA therapyW L Morison, R D Baughman, R M Day, et al.
Journal of the American Academy of Dermatology|July 25, 2000
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?G G Krueger, S R Feldman, C Camisa, et al.
Pageof 4